Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule

Osborne, RJ; Malik, Sanjeev; Slevin, M. L.; Harvey, VJ; Spona, J.; Sälzer, H.; Cj, Williams

doi:10.1038/bjc.1988.22

Cited by 30 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No patients discontinued treatment because of unacceptable toxicity. These results are similar to those found for gynecological cancer patients with normal renal function (3,5,20–27) .…”

Section: Discussionsupporting

confidence: 89%

Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction

Sirisabya

Jaishuen

et al. 2008

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Tamoxifen has been found to be safe and effective in gynecological cancer patients with normal renal function. However, to our knowledge, no data exist regarding its effectiveness and toxicity in gynecological cancer patients with chronic kidney disease (CKD). Therefore, we retrospectively evaluated the effects of tamoxifen in patients with recurrent gynecological cancer and CKD. We collected clinical and demographic data for all patients. CKD was defined as a creatinine clearance (CrCl) level of less than 90 mL/min/1.73 m(2), in accordance with the National Kidney Foundation Kidney and Dialysis Outcomes Quality Initiative, and further categorized as mild, moderate, or severe (CrCl levels of 60-89, 30-59, and <30 mL/min/1.73 m(2), respectively). Twenty-nine patients were included in the study--22 with epithelial ovarian cancer, 4 with peritoneal cancer, and 3 with fallopian tube cancer. Thirteen patients had mild CKD, 13 had moderate, and 3 had severe. Most patients had been treated with 20 mg/day of tamoxifen every 4 weeks. The median duration of treatment was 5 months (range, 1-52 months). The overall complete response, partial response, stable disease, and disease progression rates were 0%, 10%, 41%, and 48%, respectively. Twenty-one percent of patients experienced hot flashes, and 7% experienced nausea. No major adverse reactions occurred. These findings were similar to those for gynecological cancer patients with normal renal function. In conclusion, 20 mg/day of tamoxifen is safe and effective in gynecological cancer patients with CKD.

show abstract

“…No patients discontinued treatment because of unacceptable toxicity. These results are similar to those found for gynecological cancer patients with normal renal function (3,5,20–27) .…”

Section: Discussionsupporting

confidence: 89%

Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction

Sirisabya

Jaishuen

et al. 2008

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…The sample size of the included studies ranged from 9 to 155 subjects. The CBRs were assessed by RECIST criteria in 29 studies [11,13,14,[19][20][21][23][24][25][26][27][28]30,38,42,43,45,49,53,56,59,60], CA125 serum levels in 11 studies [15][16][17]39,40,44,46,48,50,52,63], not reported in 6 studies [12,22,29,41,61,62] and both in 7 studies [18,47,51,54,55,57,58]. Five studies included cohorts with only ER + tumors [16,20,54,56,…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis

Paleari

Gandini

Provinciali

et al. 2017

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Reports on tamoxifen used for persistent or recurrent epithelial ovarian cancer indicate response rates that vary from 0% to 27%. [57][58][59][60][61][62][63][64][65] The combined result of all studies is an 11.1% response rate, including 4.7% complete responses and 33.3% stabilization of disease. It is difficult to predict which patients will benefit from tamoxifen treatment as there is no apparent difference in histologic subtypes, grade of tumor, or hormone receptor values between responders and nonresponders.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Frontiers of Ovarian Cancer Therapy

Balat

Mohammed²,

Kudelka³

et al. 1996

Cancer Control

View full text Add to dashboard Cite

Since the majority of patients with ovarian cancer present with advanced stages of disease, more effective systemic approaches are needed to add to the benefits of surgical staging and debulking. New combinations of taxoids with cisplatin have prolonged survival, and other chemotherapeutic agents are being evaluated. Immunotherapy, including intraperitoneal approaches with monoclonal antibodies, cellular therapies and vaccines, hormone therapy with well-known drugs such as tamoxifen, and gene therapy give promise for the future.

show abstract

Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule

Cited by 30 publications

References 11 publications

Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction

Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction

Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis

Frontiers of Ovarian Cancer Therapy

Contact Info

Product

Resources

About